EA PHARMA CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2016-04-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.eapharma.co.jp
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 184
- Registration Number
- NCT04223960
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03922633
- Locations
- 🇯🇵
EA Pharma Trial Site, Higashi, Fukuoka, Japan
A Study of E6011 in Participants With Active Crohn's Disease
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03733314
- Locations
- 🇯🇵
2, Bunkyo, Tokyo, Japan
🇵🇱23, Centrum Badań Klinicznych - Ośrodek Badań Wczesnej Fazy, Wrocław, Poland
🇯🇵34, Kodaira, Tokyo, Japan
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT03531892
- Locations
- 🇯🇵
AJM300/CT3 trial site 57, Nagoya, Aichi, Japan
🇯🇵AJM300/CT3 trial site 9, Toyoake, Aichi, Japan
🇯🇵AJM300/CT3 trial site 79, Akashi, Hyogo, Japan
A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants
- Conditions
- Healthy Male Participants
- Interventions
- Drug: [14C]-E6007
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03444818
- Locations
- 🇬🇧
Covance Clinical Research Unit (CRU) Ltd., Leeds, West Yorkshire, United Kingdom
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- EA Pharma Co., Ltd.
- Registration Number
- NCT03390647
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT03133468
- Locations
- 🇬🇧
Covance Clinical Research Unit (CRU) Ltd, Leeds, United Kingdom
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT03092765
- Locations
- 🇯🇵
EA Pharma trial site #1, Hiroshima, Japan
🇯🇵EA Pharma trial site #2, Hiroshima, Japan
🇯🇵EA Pharma trial site, Yamagata, Japan
Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 147
- Registration Number
- NCT03018054
- Locations
- 🇯🇵
EA Pharma Trial Site #1, Toyama, Japan
🇯🇵EA Pharma Trial Site #3, Nagoya, Aichi, Japan
🇯🇵EA Pharma Trial Site #2, Saga, Japan
A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- EA Pharma Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT03014895
- Locations
- 🇯🇵
EA Pharma Trial Site, Toshima, Tokyo, Japan